- Home
- HHS vs RLYB Comparison
HHS vs RLYB Comparison
Compare HHS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- RLYB
- Stock Information
- Founded
- HHS 1923
- RLYB 2018
- Country
- HHS United States
- RLYB United States
- Employees
- HHS N/A
- RLYB N/A
- Industry
- HHS Advertising
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- RLYB Health Care
- Exchange
- HHS Nasdaq
- RLYB Nasdaq
- Market Cap
- HHS 27.3M
- RLYB 24.1M
- IPO Year
- HHS N/A
- RLYB 2021
- Fundamental
- Price
- HHS $3.71
- RLYB $0.57
- Analyst Decision
- HHS
- RLYB Hold
- Analyst Count
- HHS 0
- RLYB 2
- Target Price
- HHS N/A
- RLYB N/A
- AVG Volume (30 Days)
- HHS 21.1K
- RLYB 316.7K
- Earning Date
- HHS 11-13-2025
- RLYB 11-06-2025
- Dividend Yield
- HHS N/A
- RLYB N/A
- EPS Growth
- HHS N/A
- RLYB N/A
- EPS
- HHS N/A
- RLYB N/A
- Revenue
- HHS $174,951,000.00
- RLYB $761,000.00
- Revenue This Year
- HHS $6.54
- RLYB N/A
- Revenue Next Year
- HHS N/A
- RLYB N/A
- P/E Ratio
- HHS N/A
- RLYB N/A
- Revenue Growth
- HHS N/A
- RLYB 154.51
- 52 Week Low
- HHS $3.06
- RLYB $0.22
- 52 Week High
- HHS $7.72
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- HHS 53.28
- RLYB 49.86
- Support Level
- HHS $3.67
- RLYB $0.58
- Resistance Level
- HHS $3.83
- RLYB $0.62
- Average True Range (ATR)
- HHS 0.10
- RLYB 0.04
- MACD
- HHS 0.01
- RLYB -0.01
- Stochastic Oscillator
- HHS 67.57
- RLYB 56.07
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.